The medication is a glucagon-like peptide-1 receptor agonist that works by controlling blood sugar levels. The drug’s active ingredient is called dulaglutide. Other glucagon-like peptide-1 ...

Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China ...

As expected, Page and her team found that consuming sugar spiked blood sugar levels and triggered the release of hormones like insulin and glucagon-like peptide 1 (GLP-1), which help regulate hunger.

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

This makes oral semaglutide the first and only oral glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate cardiovascular safety and efficacy. According to Darren K. McGuire, MD ...

Mounjaro is the first drug to target both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, making it a unique treatment option in the fight against ...

The Danish pharma giant has dominated the space with its blockbuster glucagon-like peptide 1 receptor agonist (GLP-1RA) Wegovy but faces increasing competition from Eli Lilly’s Zepbound (tirzepatide) ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market. Yet ...

CVS Caremark, OptumRx and Express Scripts are pitching CVS Weight Management, Weight Engage and EncircleRx, respectively, which they say help employers provide highly coveted glucagon-like peptide ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based drugs used to treat diabetes and support weight loss. However, limited availability and high costs have made it challenging for many ...

UBT251 is a triple agonist – known colloquially as a "triple-G" medication – which targets glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.